Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.26M Sell
16,948
-48,600
-74% -$5.5M ﹤0.01% 943
2026
Q1
$7.3M Buy
65,548
+1,646
+3% +$195K 0.01% 721
2025
Q4
$8.62M Buy
63,902
+17,416
+37% +$1.9M 0.01% 694
2025
Q3
$3.95M Buy
+46,486
New +$2.85M ﹤0.01% 825

Other funds holding ABVX

TD Asset Management's ABVX Position: Q2 2026 in Review

TD Asset Management reduced its Abivax (ABVX) stake by 74% in Q2 2026, selling an estimated $5.5M and leaving 16,948 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #943.

TD Asset Management first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. The position peaked at $8.62M in Q4 2025. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • TD Asset Management held 16,948 shares of Abivax worth $2.26M as of Q2 2026.
  • TD Asset Management sold 48,600 Abivax shares in Q2 2026, an estimated $5.5M.
  • Abivax made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #943 holding.
  • TD Asset Management first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • TD Asset Management's Abivax position peaked at $8.62M in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.